Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹170 Cr
Revenue (TTM)
₹19 Cr
Net Profit (TTM)
₹2 Cr
ROE
20.5 %
ROCE
20.4 %
P/E Ratio
92.6
P/B Ratio
4
Industry P/E
38.04
EV/EBITDA
52.9
Div. Yield
0 %
Debt to Equity
0.8
Book Value
₹68.9
EPS
₹2.5
Face value
10
Shares outstanding
6,232,500
CFO
₹62.20 Cr
EBITDA
₹60.72 Cr
Net Profit
₹34.74 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Auro Laboratories
| 1.8 | 11.7 | 15.8 | 26.6 | 44.9 | 43.7 | 40.4 |
|
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
|
BSE Small Cap
| -2.6 | 9.6 | 21.0 | 6.2 | 27.3 | 35.1 | 17.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Auro Laboratories
| 97.6 | 64.2 | -26.9 | 30.0 | 76.3 | -15.8 | -28.3 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Auro Laboratories
|
273.2 | 170.2 | 19.3 | 1.6 | 11.4 | 3.6 | 92.6 | 4.0 |
| 463.8 | 4,234.9 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.2 | 3.1 | |
| 334.6 | 3,636.7 | 150.8 | 48.8 | 42.1 | 20.7 | 74.6 | 14.6 | |
| 280.7 | 2,607.9 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.6 | |
| 88.8 | 2,592.4 | 2,079.2 | 101.1 | 6.3 | 6 | 25.6 | 1.5 | |
| 64.7 | 3,537.6 | 1,811.6 | 118.0 | 8.0 | 10.4 | 30 | 3.1 | |
| 714.1 | 3,620.6 | 921.9 | 95.8 | 9.0 | 8 | 36.3 | 2.9 | |
| 2,341.5 | 3,869.3 | 653.4 | 183.2 | 21.2 | 20.9 | 21.1 | 7.3 | |
| 236.0 | 5,138.9 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 46.7 | |
| 606.1 | 4,280.0 | 2,028.9 | 150.6 | 7.5 | 6.2 | 31.1 | 1.8 |
No Review & Analysis are available.
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency,... anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India. Read more
Incorporated
1989
Chairman
Sharat Deorah
Managing Director
Sharat Deorah
Headquarters
Palghar, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Auro Laboratories Ltd stood at ₹ 99 Cr as on 31-Mar-25
The share price of Auro Laboratories Ltd is ₹273.15 (BSE) as of 13-Jun-2025 IST. Auro Laboratories Ltd has given a return of 44.94% in the last 3 years.
Auro Laboratories Ltd has a market capitalisation of ₹ 170 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Auro Laboratories Ltd is 3.96 times as on 13-Jun-2025, a 19% premium to its peers’ median range of 3.33 times.
The P/E ratio of Auro Laboratories Ltd is 92.57 times as on 13-Jun-2025, a 143% premium to its peers’ median range of 38.04 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Auro Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Auro Laboratories Ltd.
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.
The prominent promoters of Auro Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
AURO IMPEX PRIVATE LTD |
18.75%
|
|
SHARAT DEORAH |
18.71%
|
|
SIDDHARTHA DEORAH |
7.09%
|
|
SAMRIDHI DEORAH |
3.87%
|
|
SHARAT DEORAH HUF |
3.67%
|
The chairman of the company is Sharat Deorah, and the managing director is Sharat Deorah.
There is no promoter pledging in Auro Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
5,139
|
|
|
4,280
|
|
|
4,235
|
|
|
3,869
|
|
|
3,637
|
|
|
3,621
|
|
|
3,538
|
|
|
2,608
|
|
|
2,592
|
| Auro Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
3.61
|
|
Operating margin(%)
|
11.45
|
|
Net Margin(%)
|
7.77
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Auro Laboratories Ltd was ₹2 Cr.
₹-0.95
(
